BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 05/05/2010

FDA Withdraws BREVIBLOC (Esmolol Hydrochloride) Injection from Sale Due to Safety Concerns

The FDA has determined that BREVIBLOC (esmolol hydrochloride) injection, 250 milligrams per milliliter, was withdrawn from sale due to safety concerns, and the agency will no longer accept new drug applications for this product.

Source: Federal Register — Health and Human ServicesOpen original release →